MDGL
Madrigal Pharmaceuticals Inc
NASDAQ: MDGL · HEALTHCARE · BIOTECHNOLOGY
$480.77
+1.37% today
Updated 2026-06-12
Market cap
$11.08B
P/E ratio
—
P/S ratio
9.79x
EPS (TTM)
$-13.51
Dividend yield
—
52W range
$275 – $615
Volume
0.3M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
6.3
Growth
B5.5
Quality
C+2.0
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-0.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$687.00
+42.90%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy10 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 126.80% QoQ
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -0.82 — distress zone
- Thin margins at -27.30%
- Negative free cash flow $-171.28M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $180.13M | $958.40M | $1.13B | $1.8B |
| Net income | $-295.35M | $-373.63M | $-465.89M | $-288.28M | $-94.39M | — |
| EPS | — | — | — | — | $-13.51 | $-2.50 |
| Free cash flow | $-225.07M | $-325.71M | $-457.03M | $-190.02M | $-171.28M | — |
| Profit margin | — | — | -258.64% | -30.08% | -27.30% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-01 | SOERGEL, DAVID | Sale | 1,042 | $495.74 |
| 2026-05-22 | LEVY, RICHARD S | Sale | 1,497 | $517.59 |
| 2026-05-22 | LEVY, RICHARD S | Sale | 782 | $518.76 |
Peer comparison
Smart narrative
Madrigal Pharmaceuticals Inc trades at $480.77. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -0.82, it sits in the distress. TTM revenue stands at $1.13B. with profit margins at -27.30%.
Frequently asked questions
What is Madrigal Pharmaceuticals Inc's stock price?
Madrigal Pharmaceuticals Inc (MDGL) trades at $480.77, on a P/S of 9.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Madrigal Pharmaceuticals Inc overvalued?
Madrigal Pharmaceuticals Inc carries a Smart Value Score of 31/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Madrigal Pharmaceuticals Inc (MDGL)?
The 12-month analyst consensus target is $687.00, about 42.9% above the current $480.77. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of MDGL by 2030?
Our research-backed model puts the 2030 base case at $1,464.12, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Madrigal Pharmaceuticals Inc's revenue?
Madrigal Pharmaceuticals Inc's trailing twelve-month revenue is $1.13B, and our model projects it reaching about $6.38B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Madrigal Pharmaceuticals Inc's Altman Z-Score is -0.82, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio9.79x
ROE-56.94%
Beta-1.06
50D MA$511.91
200D MA$492.04
Shares out0.02B
Float0.01B
Short ratio—
Avg volume0.3M
Performance
1 week+0.00%
1 month-3.42%
3 months+12.33%
YTD-15.37%
1 year—
3 years—
5 years—